[ TRANSACTION RECORD ]

Roche Holding AG Investment in Carmot Therapeutics — 2024

VERIFIED VECTOR ID: 001907 · tx-103-2
M SOURCE NODE — FUNDER
Roche Holding AG
Healthcare Switzerland
$2,700,000,000
EQUITY
29/01/2024
Q DESTINATION NODE — RECIPIENT
Carmot Therapeutics
Company United States
Amount (USD)
$2.7B
Flow Type
EQUITY
Transaction Date
29/01/2024
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Roche Holding AG
AUM 255000
HQ Location Switzerland
Sector Healthcare
Recipient Profile [ Q ]
Entity Carmot Therapeutics
Entity Type Company
Jurisdiction United States
Intelligence Note

Roche Holding AG completed the acquisition of Carmot Therapeutics for 2.7 billion dollars to enter the rapidly growing market for obesity treatments. The transaction provides Roche with a portfolio of injectable and oral drug candidates for metabolic diseases. This deal illustrates the intense institutional competition for a presence in the weight-loss pharmaceutical sector.

Σ
Primary Forensic Source https://www.roche.com/media/releases/med-cor-2024-01-29/
✓ SOURCE LINKED